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1. Introduction 
Osteoarthritis is the most common joint disease, and is characterized by progressive loss of 
articular cartilage, subchondral bone sclerosis, osteophyte formation, synovial membrane 
changes, and an increase in synovial fluid with decreased viscosity and lubrication 
properties. Mechanical, biochemical, and genetic factors are all involved in pathogenesis of 
osteoarthritis (Chevalier, 2002; Wearing et al., 2006).  
Given the chronic and non-life-threatening nature of osteoarthritis, a good safety profile is 
essential. Characteristics of osteoarthritis vary across patients, and several definite clinical 
patterns have been identified. The choice of a suitable treatment strategy for a patient depends 
on clinical history, contraindications to specific therapies, and overall tolerability and 
acceptability of the considered treatment. This is especially true in the elderly, the major 
targeted people for osteoarthritis therapy, for whom one must consider the risk of upper 
gastrointestinal or adverse renal effects and the diverse array of concomitantly used 
medications. Intra-articular injection into osteoarthritic joints may play an important role in the 
therapeutic plan. Osteoarthritis of weight-bearing joints, such as knee osteoarthritis, is more a 
local mechanical driven disease than a generalized one. In order to reach a non-vascularized 
tissue, such as cartilage, local intra-articular administration of drugs should be considered. 
Intra-articular injections are one of the clinician’s many tools for treatment of osteoarthritis. 
Injection should be contemplated as an adjunct to the overall treatment plan-never as the 
sole component of therapy. Injections may be used diagnostically as well as therapeutically 
and are generally “safe” when used judiciously by a skilled practitioner.  
At this time, no targeted treatments for osteoarthritis have been developed. Therefore, 
preclinical and clinical research studies using other pharmacologic agents that might 
provide additional benefit are currently underway. A review of these investigational 
approaches — hyaluronic acid, recombinant human growth hormone, and platelet rich 
plasma — will be presented here. 
1.1 Rationale for intraarticular injection of osteoarthritis  
While some patients present with generalized osteoarthritis, which is thought to be strongly 
influenced by genetic factors, much of osteoarthritis of weight bearing joints can be 
regarded as a local disease driven by abnormal mechanical stress.  
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Osteoarthritis, distinct from many other diseases, is amenable to local intraarticular 
treatment as well as systemic treatment. Though most efforts so far have concentrated on 
development of systemic treatments, the agents used bear considerable risk of systemic side 
effects, such as the cardiovascular events and gastrointestinal adverse effects observed in 
association with most non-steroidal anti-inflammatory drugs and cyclooxygenase-2 
inhibitors for treatment of joint pain (Petit-Zeman, 2004; Topol, 2004). The chronic nature of 
the disease requires development of drugs suitable for chronic systemic treatment with 
minimal side effects, which is a challenging goal. Local drug application, i.e., injection of 
drugs directly into the affected joint, is an option for treatment of osteoarthritis which is 
already frequently used and has the potential to deliver the desired profile.  
In summary, progression of knee osteoarthritis results from local factors, which include 
synovial membrane inflammation, chondrocyte activation, and bone remodeling. Therefore, 
it appears logical to favor an intra-articular route for treatment of knee (as well as hip) 
osteoarthritis.  
1.2 Advantages and disadvantages of intraarticular administration compared to 
systemic administration 
The main advantage of intraarticular administration is that the drug reaches the cartilage, 
which includes no blood vessels, and, therefore, is not exposed to circulating drugs (Gerwin 
et al., 2006). Drugs given by systemic administration may also penetrate the joint fluid from 
blood via diffusion through the synovium, particularly in cases of active synovitis, as in 
rheumatoid arthritis. Because the superficial cartilage is altered in osteoarthritis, drugs 
present in high concentrations in the joint fluid may be able to penetrate within the cartilage 
by passive diffusion. However, short residence time due to rapid uptake by circulation 
imposes a major challenge in intra-articular delivery of solutions and correlates with the 
severity of synovitis (which accelerates drug clearance) (Gerwin et al., 2006). For instance, 
most hyaluronic acid preparations remain in the joint for only a few hours (half-life, 17 h) 
(Brandt et al., 2000). This emphasizes the need for development of sustained-release 
formulas that support continuous release of the drug from a depot in the joint space over a 
period of several weeks to months.  
In the effort to achieve an increase in drug residence time in the synovial cavity, drug 
delivery systems may be used. Among them, thermally responsive elastin-like polypeptide 
gels capable of spontaneous aggregation after intraarticular injection represent a simple and 
innovative way to prolong the intraarticular half-life of a drug. These aggregating elastin-
like polypeptides form a drug-depot, resulting in a 25-fold longer half-life than drugs 
administered with a non-aggregating protein (Betre et al., 2006). Besides the thermo-gelling 
approach, which is used to increase the retention time of a drug formulation in the joint, pH-
sensitive gels are interesting tools. For instance, an intra-articularly injected sustained-
release vehicle, such as gelatin hydrogel microspheres, for platelet rich plasma appeared to 
stimulate cartilage matrix metabolism, suggesting its potential for use in osteoarthritis 
treatment (Saito et al., 2009). 
Aspiration and injection into the knee or other joints is a common technique for both 
diagnostic and therapeutic purposes, in spite of practical difficulties, such as the lack of 
accessibility of the joint, and, thus, obstructed needle placement (Jackson et al., 2002). 
Although rare, complications of intraarticular injections, such as infection, post-injection 
flare, crystal-induced synovitis, cutaneous atrophy, and steroid arthropathy (Neustadt, 
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2001),  could result in dramatic side effects. The incidence of septic joints related to local 
steroid injection is about 1 in 10 000 injections, while for post-injection flare, a frequency of 
around 2% has been reported. Inappropriate injection technique, inexact needle placement, 
and blockage of synovial outflow by viscous injections have all been suggested as causative 
factors for development of acute pseudoseptic arthritis (Chen et al., 2002) Therefore, proper 
needle placement within the intraarticular joint deserves careful attention.  
1.3 Technical consideration of intraarticular administration 
Although an intra-articular injection of the knee is not a complex procedure, assessment of 
whether the tip of the needle lies free in the joint or is embedded in synovium or soft tissue 
before administration of the preparation of medication could be difficult. Some recent 
studies have called into question the ability of physicians to accurately localize such 
injections, finding that almost a third of knee injections are inaccurate (Jones & Doherty, 
2003). This finding emphasizes the importance of proper needle placement. Needle 
placement is easily confirmed when an effusion is present. The return of synovial fluid 
documents intra-articular placement of the needle. In the absence of an effusion, needle 
placement requires the use of anatomic landmarks and tactile feed-back to help the operator 
in positioning of the needle. Prior to performance of an injection, all landmarks for entry 
into the joints were outlined with a marking pen (Fig. 1.).  
 
 
Fig. 1. All landmarks were outlined with a marking pen. A. Landmarks for lateral and 
medial mid-patellar injections sites. B. Landmarks for anteriomedial and anteriolateral 
injections sites. C. Lateral mid-patellar injection were performed with the lower limb 
extended on the examination table. D. Anteriolateral injection were performed with the knee 
in flexed position. E. Anteriolateral injection via ultrasound guidance were performed with 
the knee in flexed position. 
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The operator then stands level with the other knee. With one hand, the patella is pushed up 
and toward the operator, which causes the lateral/medial edge to become more prominent. 
Lateral mid-patella and medial mid-patella injections were administered with the lower 
extremity extended on the examination table. The needle was advanced transversely 
between the articular surfaces of the patellofemoral joint at the midpoint of the patella. 
Jackson et al. evaluated the accuracy of needle placement in 80 obese patients undergoing 
treatment for symptomatic degenerative joint disease (Jackson et al., 2002). They reported 
difficulty in establishing anatomical landmarks about the knee due to obesity. A large 
quantity of subcutaneous fat also increases the distance between the skin and the joint space. 
They used anteromedial, anterolateral, and lateral mid-patella portals. Results of their study 
demonstrated that injection through the lateral mid-patella approach had an accuracy of 
93%. They explained that, when this route is used, the needle passes through a minimal 
amount of soft tissue in order to reach the intra-articular space; therefore, they 
recommended use of the lateral mid-patella portal with the knee extended. The extended leg 
lateral midpatellar approach has been shown to be highly accurate (93%) (Fig. 1.) (Jackson et 
al., 2002). In patients with severe osteoarthritis, the midpatellar approach may be impractical 
due to hindrance of the injection pathway by patellofemoral osteophytes (Jackson et al., 
2002). To overcome this problem, anteriolateral and anteriomedial injections were 
performed with the patient’s leg hanging over the side of the examination table with the 
knee flexed to approximately 90 degrees (Fig. 1). On the basis of careful palpation of 
anatomical landmarks, the injection site was selected inferior to the patella, one finger 
breadth proximal to the joint surface, and either medial or lateral to the patellar tendon. The 
needle was directed obliquely toward the intercondylar notch. While accessing the 
anteriolateral and anteriomedial approach with the patient in the sitting position with the 
knee bent, these approaches provide only 71-75% accuracy (Neustadt, 2006). Improvement 
of accuracy has been attempted through use of ultrasound techniques; the operator placed 
the long axis of the ultrasound transducer over the anteriomedial portion of the knee (Fig. 
1.). The modified anteriolateral bent knee approach has been reported to be an effective, 
accurate, and equivalent alternative to the standard lateral midpatellar approach for 
intraarticular injection of the knee (Chavez-Chiang et al., 2011). Therefore, any of these 
approaches might be preferred, depending on the experience of the physician. On the other 
hand, 100% accuracy could not be obtained through any approach, which should be kept in 
mind when treating knee problems with intra-articular injections. Injections were 
administered using a 5 ml syringe, with a 4 cm long needle. Injection and aspiration of the 
knee is commonly used for both diagnostic and therapeutic purposes. Determination of 
whether the needle tip lies freely within the joint or is embedded in the synovium or other 
intra-articular tissues may be difficult. In addition, clinical experience has shown that intra-
articular injection is more painful when the tip of the needle is placed in Hoffa’s fat pad. 
2. Special focus on three intraarticular administration regimens 
2.1 Current most available intraarticular injection fromulation for treatment of 
osteoarthritis: Hyaluronic acid 
2.1.1 Basic concept of hyaluronic acid 
Hyaluronic acid is a very long polysaccharide chain, consisting of repeating disaccharide 
units of N-acetyl-glucosamine and glucuronic acid. The average molecular weight of 
synovial fluid hyaluronic acid is 5 to 7 × 106 d, or 12,500 disaccharide units (Balazs & 
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Denlinger, 1993). Endogenous hyaluronic acid is synthesized by type B synoviocytes and 
fibroblasts in the synovium and released into the joint space. Hyaluronic acid is a major 
component of synovial fluid and articular cartilage, and is an important contributor to joint 
homeostasis (Balazs & Denlinger, 1993). The viscoelasticity and rheology of synovial fluid is 
due entirely to its hyaluronic acid content. 
Hyaluronic acid contributes to the viscous and elastic properties, affording the synovial fluid 
the peculiar capacity to function differently under distinct loading conditions (Simon, 1999). 
Viscosity is defined as the ability to dissipate mechanical energy as heat during low shear 
stress; elasticity is the ability of a molecule to absorb mechanical energy under increased loads. 
In the presence of low shear forces with slow joint movements, the hyraluronic acid solution 
exhibits high viscosity with reduced elasticity and acts as a joint lubricant. With increased rates 
of joint motion (high shear), this is reversed as the synovial fluid becomes more elastic and acts 
as a shock absorber (Balazs & Denlinger, 1993). The normal adult knee contains approximately 
2 mL of synovial fluid, with a hyaluronic acid concentration of 2.5 to 4.0 mg/mL (Watterson & 
Esdaile, 2000). In patients with osteoarthritis, the concentration and molecular weight of 
hyaluronic acid in synovial fluid is reduced by a factor of 2 or 3, owing to both degradation 
and dilution. Furthermore, the molecular weight of the hyaluronate that is present is reduced 
to as low as 2 × 105 d (Balazs & Denlinger, 1993). These consequences lead to dramatic changes 
in the viscoelastic properties of the synovial fluid, and, thus, altered joint mechanics. 
Decreased lubrication leads to increased stress upon the already diseased cartilage, further 
disrupting the collagen network and the integrity of the chondral surface (Marshall, 2000). 
Cartilage nutrition and waste removal are also adversely affected. Beyond these mechanical 
properties, hyaluronic acid has been reported to serve other significant functions within the 
joint (See Table 1-hyruan injection review). Higher molecular weight hyaluronic acid has been 
shown to influence a variety of leukocyte functions, including migration, chemotaxis, 
phagocytosis, adherence, and proliferation. In vitro studies have further demonstrated effects 
on levels of prostaglandins and cyclic AMP in synovial fluid. In addition to these anti-
inflammatory properties, analgesic activity of hyaluronic acid has been demonstrated in both 
in vitro and animal studies (Ghosh, 1994). This may be mediated both directly via inhibition of 
nociceptors and indirectly through decrease of synthesis of or binding to bradykinin, 
substance P, and other hyperalgesic compounds. 
Hyaluronic acid may have a chondroprotective effect, inhibiting degradation of cartilage, as 
well as encouraging its healing and repair. Ghosh (Ghosh, 1994) conducted de novo HA 
biosynthesis by fibroblasts upon in vitro exposure to exogenous hyaluronic acid. The efficacy 
of intra-articular injection can be influenced by the concentration and molecular weight of 
exogenous hyaluronic acid, with molecular weights greater than 5 × 106 being the most 
effective. Lower molecular weight hyaluronic acid compounds did not elicit a significant 
biosynthetic response. The author also reported that high molecular weight cross-linked 
derivatives of hyaluronic acid (hylans) provided a protective effect on chondrocytes exposed 
to cytokines (IL-1), oxygen-derived free radicals, or leukocyte proteinases. This effect was 
reversible and viscosity dependant; higher molecular weight hyaluronic acid may yield more 
superior protection than those with lower molecular weights.   
2.1.2 History and development of HA 
In the late 1960s, Balazs and coworkers (Balazs & Denlinger, 1993) conducted extensive 
research into joint fluid rheology and hyaluronic acid, which resulted in definition of the 
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concept of ‘‘viscosupplementation’’. Nearly 2 decades would pass before clinical application 
was achieved. Original source material for study was derived from both human umbilical 
cord tissue and rooster combs. Subsequently, the noninflammatory fraction of sodium 
hyaluronan (NIF-NaHA) was developed for therapeutic use in both joint 
viscosupplementation and ophthalmic viscosurgery. This product (marketed as Healon or 
Hyartil-Vet) was subsequently used, with some reported success, for treatment of traumatic 
joint injury in race horses beginning in 1975 (Marshall, 2000). In the late 1980s, 2 NIF-NaHA 
products, Artz (Seikagaku, Japan) and Hyalgan (Fidia,Italy), were placed on the market 
overseas for use in human arthritic joints. Because both formulations were lower in 
molecular weight, clinical recommendations were for 5 weekly injections. Hylans has been 
reported to improve viscoelastic properties and increase residual time within the joint, as a 
function of cross-linking. Two forms, a fluid (hylan A) and a gel (hylan B), were produced. 
Exogenous hylan A has been demonstrated to remain in the knee joint for approximately 1 
week after injection; hylan B may be present for as long as 30 days after injection. Hylan G-F 
20 (Synvisc) was the first (and remains the only) commercially available cross-linked 
hyaluronic acid in the United States. Hylan G-F 20 consists of a combination of the fluid and 
gel forms at a 4:1 ratio (or 20% gel). Its molecular weight is 6 × 106 d, similar to that of 
hyaluronic acid in a healthy joint. By comparison, the molecular weight of Hyalgan is 
significantly less (between 5.0 and 7.3 × 105 d). Viscosupplementation with intra-articular 
hyaluronic acid was first approved by the Food and Drug Administration in 1997. Several 
different formulations of hyaluronic acid from diverse sources, and with varying 
composition and molecular weight, are available in the United States for intra-articular 
injection. By obtaining approval under the category of a ‘‘biologic device,’’ these agents are 
indicated for treatment of pain in patients with osteoarthritis who have failed to respond to 
conservative treatment, such as non-pharmacological therapy and simple analgesics. Each of 
these agents (Table 2) has distinct properties, dosing instructions, cost, and, possibly, clinical 
outcomes. Viscosupplementation is currently indicated only for treatment of patients with 
osteoarthritis of the knee. It has been accepted as part of the American College of 
Rheumatology guidelines for treatment of osteoarthritis and the American Academy of 
Orthopedic Surgeons guidelines for treatment of osteoarthritis of the knee.  
Hyraluronic acid formulations can be obtained by prescription or directly from the 
clinician’s office, and are dispensed in 2 mL vials or 2 mL prefilled syringes. Currently, the 
recommended injection schedules are 1 injection weekly for 3 weeks for the cross linked 
higher molecular weight injection, such as hylan G-F 20. All of these products, except for 
Euflexxa, are contraindicated in patients with a hypersensitivity to poultry. Any knee 
effusion should be aspirated before injection in order to prevent dilution of the 
viscosupplement (Vad et al., 2003). Excessive weight-bearing and activity are limited for 48 
to 72 hours after each injection. Repeat courses of viscosupplementation are Food and Drug 
Administration approved, and have generally led to a 6-month interval period between 
injections (Raynauld et al., 2005) 
2.1.3 Safety profile of hyraluronic acid 
The safety profile of intra-articular hyaluronans is very favorable, and, because they are used 
as a local therapy, there are no known drug interactions-an advantage for patients receiving 
treatment for comorbid conditions. The total incidence of side effects has been reported to be 
approximately 1% to 4% per injection (Hammesfahr et al., 2003). The most frequent adverse 
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effect is local reaction in the injected knee, including mild pain, swelling, warmth, and/or 
redness at the site of injection. Such reactions are usually temporary, lasting 1 or 2 days, and 
generally respond well to physiotherapy and non-steroidal anti-inflammatory drugs. In one 
large, retrospective review of viscosupplementation with hylan G-F 20 (Synvisc), local adverse 
reactions developed in 28 of 336 patients, with an overall rate of 2.7% per injection. Incidence 
of adverse events was found to be significantly affected by the injection technique, with a side 
effects response rate of 5.2% with a medial approach in a flexed knee, versus 1.7% when 
injected laterally in extension (Hammesfahr et al., 2003). Adverse reactions may be related 
more to the accuracy of intra-articular injection than the substance itself. As previously 
mentioned, injection technique is very important. There is growing evidence that hylan G-F 20 
in particular may be associated with an adverse event, which has been termed pseudosepsis, 
or a severe acute inflammatory reaction (Goldberg & Coutts., 2004). This phenomenon has 
been associated with cross-linked hyaluroic acid. This clinical entity appears to be distinct 
from previously described minor local inflammatory reactions uncommonly seen with all 
hyaluronic acid preparations. Pseudosepsis presents as a severe inflammatory process of the 
joint, with a large effusion, and significant pain occurring within 1 to 3 days of injection. 
Differential diagnosis is requested from true sepsis or inflammatory arthritis, requiring 
synovial aspiration and examination. Aspirates of patients with pseudosepsis typically show a 
moderate cell count with high numbers of mononuclear cells (eosinophils, neutrophils, and 
macrophages), and the absence of organisms or calcium pyrophosphate crystals.  
Pseudosepsis characteristically occurs after previous injection, such as upon receiving the 
second or third injection in the first course. One report documented a 10-fold increase in the 
rate of reactions in patients 
undergoing a repeat course of hylan G-F 20 viscosupplementation (Leopold et al., 2002). As 
a result, some authors have supposed an immunologic etiology for this process (Leopold et 
al., 2002). However, in a recent prospective study comparing aspirates from 16 patients who 
presented with a severe acute inflammatory reaction after Synvisc treatment with 20 
aspirates from control patients with osteoarthritis, analysis was notably more consistent 
with a type 4 (cell-mediated) hypersensitivity reaction than with an antibody-mediated 
reaction (Marino et al., 2006). The frequent presence of eosinophils further supports these 
findings. To date, sodium hyaluronates (Hyalgan, etc) have not been reported to trigger this 
process, suggesting a link between pseudosepsis and chemical cross-linking modification of 
the hyaluronic acid molecule in hylan synthesis (Synvisc). Pseudosepsis requires 
symptomatic treatment, including use of modalities, activity modification, analgesics, and 
non-steroidal anti-inflammatory drugs. Arthrocentesis is recommended in order to rule out 
sepsis, and can be helpful in palliation. Once infection has been excluded, intra-articular 
steroids may be of value (Goldberg & Coutts., 2004). 
2.1.4 Preclinical studies 
Chondroprotective effects of hyaluronic acid were observed in vitro, e.g., that it stimulates 
production of tissue inhibitors of matrix metalloproteinases by chondrocytes, inhibits 
neutrophil-mediated cartilage degradation, and attenuates interleukin-1 induced matrix 
degeneration and chondrocyte cytotoxicity (Brockmeier & Shaffer, 2006). In several studies 
hyaluronic acid was found to enhance prostaglandin synthesis and to decrease prostaglandin  
breakdown and release from cartilage matrix (Moreland, 2003). In addition, it was shown to 
normalize endogenous hyaluronic acid synthesis by synoviocytes (Vuorio et al., 1982). 
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There has been considerable controversy with regard to whether hyaluronic acid has 
structure-modifying effects. A number of animal models have been conducted for 
experimental induction of changes associated with osteoarthritis, such as degradation of 
collagen and proteoglycans of articular cartilage, and increased inflammation. The most 
commonly studied models have been total or partial meniscectomy and anterior cruciate 
ligament transection; it should be noted that these models are quite aggressive in that 
degenerative changes can occur within a few months after induction. Using these 
approaches, potential structure-modifying activities of exogenously added hyaluronic acid 
have been demonstrated in several species. Wiig et al. (Wiig et al., 1990) reported that 
administration of a single injection of Healon_(sodium hyaluronate, MW 1900 - 3900 kDa) 
(Pharmacia & Upjohn, Uppsala, Sweden) immediately after anterior cruciate ligament 
transection in rabbits resulted in significantly decreased inflammation, increased collagen 
synthesis, increased angiogenesis, and enhanced tissue repair, compared with a single 
injection of saline.  
The structure-modifying effects of hyaluronic acid have been investigated using a 
meniscectomy model in rabbits and sheep. Injection of Artz (Supartz, sodium hyaluronate, 
MW 620 - 1170 kDa) after partial meniscectomy in rabbits or sheep resulted in significantly 
inhibited cartilage degeneration (Kikuchi et al., 1996; Armstrong et al., 1994). Five weekly 
intraarticular injections of sodium hyaluronate, initiated immediately after partial or total 
meniscectomy, resulted in significantly enhanced collagen remodeling, compared with 
saline injections (Sonoda et al., 1997, 2000). A course of 5 weekly injections of Artz (Supartz, 
sodium hyaluronate, MW 620 - 1170 kDa) was found to protect chondrocytes from apoptotic 
cell death following anterior cruciate ligament transection in a rabbit model (Takahashi et al, 
2000). 
Following administration to either rabbits or dogs after anterior cruciate ligament 
transaction, Artz (Supartz, sodium hyaluronate, MW 620 - 1170 kDa) was also found to 
decrease the degree of damage to femoral cartilage and aided in preservation of articular 
cartilage and integrity of synovial tissue (Yoshioka et al., 1997; Shimizu et al., 1998). 
In a study for evaluation of the effects of Synvisc (hylan G-F 20, MW >6000 kDa) (Biomatrix, 
Montreal, Canada) in a dog anterior cruciate ligament transection model, gross 
morphological and histological damage within joints that received injections was 
significantly milder than that seen in control joints (Marshall et al., 2000). Similar results 
were obtained in rabbits and dogs using Hyalgan (sodium hyaluronate, MW 500 - 730 kDa). 
A course of 5 weekly Hyalgan injections, starting at 4 or 13 weeks after anterior cruciate 
ligament transection, resulted in a significantly reduced degree of articular degeneration at 
evaluations performed 26 weeks after surgery. In this study, rabbits who received 10 
injections showed less disease progression than did rabbits treated with five injections, 
suggesting that a sequential course of Hyalgan therapy may provide long-term benefits for 
altering the disease course (Amiel et al., 2003). In dogs, initiation of weekly IA injections of 
sodium hyaluronate starting at 3, 6, or 12 weeks after anterior cruciate ligament transection 
(the Pond-Nuki model of osteoarthritis) resulted in significantly inhibited formation of a 
fibroblast-like cell layer on the articular cartilage and increased mean chondrocyte density 
and area in the middle and deep layer of the articular cartilage (Schiavinato et al., 1989). 
When given starting at 3, 6, or 12 weeks after anterior cruciate ligament transection in dogs, 
Hyalartz (sodium hyaluronate, MW 500 - 750 kDa) was found to induce a significant 
reduction in cartilaginous lesions (Pond-Nuki model of osteoarthritis) (Wenz et al., 2000). 
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On the other hand, injection of hyaluronic acid into sheep joints subjected to meniscectomy 
resulted in significantly more extensive osteophytosis and cartilage fibrillation and 
reduction in proteoglycan synthesis. A striking reduction in proteoglycan concentration in 
cartilage was also observed in dogs with anterior cruciate ligament transection who received 
prophylactic treatment with a series of hyaluronic acid injections. These findings raised 
concerns that hyaluronic acid treatment could aggravate joint damage in osteoarthritis. 
Safety and efficacy of intraarticular hyaluronic acid for treatment of pain of osteoarthritis of 
the knee have been demonstrated; preliminary work supports use of hyarluronic acid for 
osteoarthritis pain relief in other joints as well. Based on preclinical data, there is evidence to 
support the notion that all hyaluronic acids approved in the US may have some structure-
modifying characteristics. Work in these areas is ongoing. 
2.1.5 Clinical studies 
The first human clinical trial of intra-articular hyaluronic acid for treatment of arthritis was 
published by Peyron and Balazs in 1974.  
A large number of clinical trials have been conducted with different hyaluronic acid 
preparations, several of which involve large, multicenter, blinded, randomized, placebo-
controlled studies. Early clinical trials attempted to establish the clinical safety of intra-
articular hyaluronic acid and its clinical superiority in comparison with placebo (Table 2). 
Some of these studies have provided evidence that hyaluronic acid preparations are more 
effective than placebo in reducing pain associated with osteoarthritis (Dixon et al., 1988; 
Dougados et al., 1993) In contrast, others were unable to demonstrate any significant 
difference when compared with placebo groups (Henderson et al., 1993; Dahlberg et al., 
1994). 
Recent attention has focused on comparison of intra-articular viscosupplementation with 
other osteoarthritis treatment methods (such as oral anti-inflammatories and intra-articular 
steroid injections). In a multicenter trial in Canada, Adams et al compared the 3 treatment 
arms: oral non-steroidal anti-inflammatory drugs alone, hylan G-F 20 treatment (3 weekly 
injections), and combined oral non-steroidal anti-inflammatory drugs and hylan G-F 20 
treatment. Patients took their ‘‘usual’’ non-steroidal anti-inflammatory drugs in the 
appropriate arms. At 12 weeks, all 3 of the groups showed improvement, but no statistical 
difference was observed between groups. However, at the 26-week time point, both the 
hylan G-F 20 only and combined non-steroidal anti-inflammatory drugs and hylan G-F 20 
groups were statistically superior to the non-steroidal anti-inflammatory drugs only group 
(Adams et al., 1995). In another large, prospective study, Altman et al compared 5 weekly 
injections of sodium hyaluronate with a placebo group and with a group of patients treated 
with oral Naproxen. On the basis of visual analog scores and the Western Ontario and 
McMaster University Osteoarthritis Index, the hyaluronate group was found to be superior 
to the placebo group at 26 weeks. The hyaluronic acid group also tended to show improved 
outcomes, compared with the non-steroidal anti-inflammatory drugs group; however, this 
finding did not show statistical significance (Altman et al., 1998). Three recent prospective 
studies have been conducted for comparison of intra-articular hyaluronic acid to intra-
articular corticosteroids. In 1 randomized, blinded comparative trial, 63 patients were 
stratified to receive 5 weekly injections of sodium hyaluronate or 1 injection of 
triamcinolone followed by 4 placebo injections. Patients were followed for 6 months with 
VAS assessments of pain with trends suggesting some benefit of viscosupplementation over 
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intra-articular steroids. However, due to a high drop-out rate, the findings were not 
statistically significant (Jones et al,, 1995). Leopold et al conducted a prospective comparison 
of 2 cohorts of patients with knee osteoarthritis. Patients in the first group received 3 weekly 
injections with hylan G-F 20, whereas those in the second group received 1 injection of intra-
articular betamethasone, and were able to request 1 additional corticosteroid injection if 
needed, over the course of the study. Although both groups showed improvement, at 6 
months, no significant difference was noted between the 2 cohorts with respect to WOMAC 
scores, VAS, or the Knee Society Scoring System (Leopold et al., 2003). In a more recent 
report from the Synvisc 901 study group, Caborn et al used the Western Ontario and 
McMaster University Osteoarthritis Index and Visual analogue scores pain scores to 
compare the 2 groups of patients who received either 3 weekly injections of hylan G-F 20 or 
1 isolated injection of triamcinolone. This study was not blinded. In their study, maximal 
benefit was noted at week 2 for the steroid group and at week 12 for the hylan G-F 20 group. 
From week 12 through week 26, significantly superior outcomes were observed in patients 
treated with hylan G-F 20 when compared with those treated with intra-articular steroids 
(Caborn et al., 2004). 
In the most recent meta-analysis from the Cochrane database, one research study obtained 
76 randomized placebo-controlled trials that fulfilled strict study design and methodology 
criteria. On the basis of their analysis of the literature, the authors concluded that 
viscosupplementation is an effective treatment for osteoarthritis of the knee, with favorable 
effects on pain, function, and patient global assessment, particularly during weeks 5 to 13 
after the injection period (Bellamy et al., 2006).  
Conservative treatments for osteoarthritis may be characterized as symptom-modifying or 
disease-modifying drugs. As defined by the Osteoarthritis Research Society, disease-
modifying drugs are those that are intended to prevent, retard, stabilize, or reverse 
development of morphological changes of osteoarthritis (Altman et al., 1996). At present, no 
pharmacological treatments for osteoarthritis have been approved for the indication of 
modifying the rate of osteoarthritis disease progression. Intra-articular hyaluronic acid is 
currently indicated only as a symptom-modifying treatment for osteoarthritis of the knee. 
However, evaluation of novel agents and agents with established symptom-modifying 
activity for disease-modifying effects has become a major focus of research on osteoarthritis. 
In an effort to obtain evidence for disease-modifying efficacy of hyaluronic acid injections, a 
large number of clinical trials have been conducted with different hyaluronic acid 
preparations over the past 25 years. However, there is substantial evidence to suggest that 
hyaluronic acid in certain patient populations can also have disease modifying activity. This 
possibility was initially suggested by the finding that the pain-relieving benefit of 
intraarticular hyaluronic acid generally persists for considerably longer than its half-life 
within the injected joint, which has been estimated in animal studies to be as short as 18 to 
24 h (Sakamoto et al., 1984). For example, clinical efficacy in randomized, controlled trials 
has been demonstrated to last for at least 26 weeks for Hyalgan®(sodium hyaluronate, 
average molecular weight 500 -730 kDa) (Altman et al., 1998) and may last as long as a year 
or more in some patients (Kotz & Kolarz, 1999). Similarly, Synvisc_ (hylan G-F 20, average 
MW >6000 kDa) (Wobig et al., 1998) (Genzyme Biosurgery, Cambridge, MA), and Supartz® 
(sodium hyaluronate, average MW 630 - 1120 kDa) (Puhl et al., 1993) (Seikagaku 
Corporation, Tokyo, Japan) have also demonstrated months of pain relief. Although many 
of these studies were well designed, the results are difficult to interpret due to a number of 
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factors. A number of these studies used highly subjective, non-validated rating scales. 
Different formulations and treatment regimens were often used, limiting study 
comparisons. Patient treatment groups were often heterogenous, leading to stratified 
outcomes based on characteristics such as age and disease severity. 
The ideal candidate for intra-articular hyaluronic acid has yet to be clearly defined. Despite 
clinical evaluations, age, symptoms, and disease severity have not proven helpful in 
identifying patients who may best benefit. One early placebo-controlled trial indicated 
increased benefit among older patients with more significant osteoarthritis. (Lohmander et 
al., 1996) 
In another study, Dahlberg et al evaluated a group of patients with normal radiographs and 
early arthritic changes observed at arthroscopy. They reported no significant benefit from 5 
weekly injections of sodium hyaluronate (compared with placebo) (Dahlberg et al., 1994). 
Despite failure to identify the optimal cohort, there is reason to believe that the greatest 
potential benefit of hyaluronic acid would likely be among younger patients, as some 
clinical data have suggested that younger patients are more likely to respond. In a meta-
analysis by Wang et al, 35 patients older than 65 years of age and those with the most 
advanced stages of arthritic change (ie, complete loss of joint space) were found to be less 
likely to show improvement with hyaluronic acid therapy. Jubb et al., in a large, 
randomized study for evaluation of the disease-modifying effects of sodium hyaluronate in 
knee osteoarthritis, demonstrated that viscosupplementation, compared with placebo, 
significantly reduced the radiographic progression of joint space loss in the subset of 
patients with a higher joint space area at study entry. Currently, intra-articular hyaluronic 
acid therapy should be considered in patients who have failed standard non-pharmacologic 
and pharmacologic treatment options, those who have a contraindication to non-steroidal 
anti-inflammatory drugs, and those who are trying to delay or are poor candidates for 
surgical treatment. (Jubb et al., 2003) 
2.2 Candidate drugs for disease-modifying intraarticular injection regimens 
Metabolism of mature articular cartilage is regulated by a number of growth factors that are 
delivered from cellular production within the cartilage, as well as from the synovial fluid 
and surrounding tissues. As the mechanisms of action for these growth factors are obtained 
through well-defined in vitro studies, it is becoming clear that growth factors may 
eventually serve to augment current cartilage repair techniques. 
Chemotactic growth factors may be used to encourage cell migration to an injury site. Cell 
numbers can be increased and matrix production up-regulated by release of appropriate 
local growth factors via scaffolds or other methods of intra-articular administration.  
Growth factors are a group of biologically active polypeptides produced by the body, which 
can stimulate cellulardivision, growth, and differentiation. In articular cartilage, numerous 
growth factors work in concert to regulate development and homeostasis of articular 
cartilage throughout life (Goldring et al., 2009). Therefore, growth factors offer promising 
treatments for enhanced regeneration of cartilage in situations of widespread cartilage loss, 
such as those that occur in osteoarthritis. When considering an osteoarthritic joint, the 
effects of any treatment, such as growth factors, on cartilage, synovial lining, ligaments, 
tendons, meniscus, any exposed subchondral bone, as well as on mesenchymal stem cells 
that gain access to the articular environment should be collectively considered. Numerous 
anabolic growth factors stimulate chondrocyte synthesis of proteoglycans, aggrecan, and 
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type II collagen, induce synoviocyte and mesenchymal stem cell proliferation, drive 
chondrogenic differentiation of mesenchymal stem cells, and decrease the catabolic effects of 
cytokines, such as interleukin-1 and matrix metalloproteinases. In addition to being 
proanabolic and anticatabolic to restoration of cartilage in naturally occurring disease, an 
ideal growth factor for general cartilage tissue engineering or regeneration in osteoarthritis 
would be effective regardless of the patient’s age or the presence of osteoarthritis and would 
have no detrimental effects on either cartilage or the synovial lining.  
Historically, most growth factors have been evaluated on an independent basis, rather than 
in combination, in order to assess their effects on cartilage homeostasis in vitro or in vivo. 
Given the array and interactions of growth factors necessary for proper cartilage 
development and homeostasis, it is unlikely that any single growth factor will lead to 
complete cartilage repair or affect the arthritic milieu, but rather a combination approach 
will be required. 
In the following review, some key players are portrayed comprehensively. Obviously, the 
collected insights indicate a major potential for regulation of cartilage and chondrocytes in 
disease and regeneration within the organism and in tissue engineering if the structural 
properties and dynamics of natural hormone activity are carefully considered. Individual 
characteristics of growth factors are described. 
Transforming Growth Factor-b1 stimulates chondrocyte synthetic activity and decreases the 
catabolic activity of interleukin-1 (Blaney et al., 2007). In vitro, Transforming Growth Factor-
b1 stimulates chondrogenesis of synovial lining and bone marrow-derived mesenchymal 
stem cells (Fan et al., 2010; Kurth et al., 2007). In addition, promising studies in rabbits have 
demonstrated Transforming Growth Factor-b1-enhanced repair of cartilage defects (Diao et 
al., 2009). However, in mouse and rabbit animal studies, numerous deleterious side effects 
of Transforming Growth Factor-b1 supplementation have been announced, including 
stimulation of synovial proliferation and fibrosis, attraction of inflammatory leukocytes to 
the synovial lining, and induction of osteophyte formation (Bakker et al., 2001; Blaney et al., 
2007). Given these serious safety concerns, which are not components of other growth 
factor-based strategies, Transforming Growth Factor-b1 therapy is not presently a suitable 
option for use in the articular environment.  
Insulin like growth factor is a circulating cytokine that reaches articular cartilage through 
the synovial fluid. Insulin like growth factor is a single polypeptide with protein sequencing 
similar to that of insulin. Insulin like growth factor -1 is the main anabolic growth factor for 
articular cartilage. 
It plays a key role in cartilage homeostasis, balancing proteoglycan synthesis and 
breakdown by chondrocytes. In vitro studies have demonstrated that Insulin like growth 
factor -1 stimulates proteoglycan production in a dose-dependent manner, as evidenced by 
increased [35S]-sulfate incorporation (Coutts et al., 1997). Similarly, Insulin like growth 
factor -1 has been shown to slow proteoglycan catabolism in a dose-dependent fashion 
(Hickey et al., 2003). 
The role of Insulin like growth factor -I in articular cartilage metabolism in both health and 
disease has been extensively evaluated (Denko et al., 1994; MaQuillan et al., 1986; Middleton 
et al., 1996; Posever et al., 1995; Wang et al., 1995). When added exogenously to monolayer 
or explant cultures of normal articular cartilage from a variety of species, Insulin like growth 
factor-I induces a plethora of anabolic effects and decreases catabolic responses (Sah et al., 
2008; Schalkwijk et al., 1989; Tyler 1989). Chondrogenic differentiation of mesnechymal stem 
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cells is induced by Insulin like growth factor-I, but is enhanced when Insulin like growth 
factor -I and Transforming Growth Factor-b1 are used in combination (Longobardi et al., 
2006; Worster et al., 2001). The premise that Insulin like growth factor-I is required for 
maintenance of articular cartilage integrity is supported by an in vivo study in rats in which 
chronic Insulin like growth factor-I deficiency led to development of articular cartilage 
lesions (Ekenstedt et al., 2006). In animal models, Insulin like growth factor-I has led to 
enhanced repair of extensive cartilage defects and protection of the synovial membrane 
from chronic inflammation (Fortier & Miller, 2006; Goodrich et al., 2007). However, studies 
of human articular cartilage indicate that serum Insulin like growth factor-1 levels and 
chondrocyte responsiveness to Insulin like growth factor-1 diminish progressively with age 
(Ashton & Matheson, 1979; Boehm et al., 2007; Fortier & Miller, 2006; Loeser et al., 2002; 
Loeser et al., 2000; Martin et al., 1997; Trippel, 1995) This finding suggests that a 
simultaneous decrease in the amount of Insulin like growth factor-1 available and a reduced 
ability of cells to respond to the remaining Insulin like growth factor may produce cartilage 
that is less capable of maintaining its structural and functional integrity. Insulin like growth 
factor non-responsiveness has been further observed to exist in chondrocytes from arthritic 
cartilage or in the presence of inflammation (Verschure et al., 1996). The cellular response to 
Insulin like growth factor-1 is receptor mediated and Insulin like growth factor binding 
proteins in synovial fluid appear to regulate the amount of free Insulin like growth factor-1 
available for receptor binding (Trippel, 1995). 
Age-related decline in the responsiveness of chondrocytes to Insulin like growth factor-1 
appears to be due at least in part to overexpression of Insulin like growth factor binding 
proteins. Chondrocytes from patients with osteoarthritis have been observed to generate 
excessive levels of Insulin like growth factor-1 binding proteins (Martin et al., 1997; van den 
Berg et al., 1999). It has also been suggested that a defect in Insulin like growth factor 
receptor binding or postreceptor signaling may contribute to Insulin like growth factor non-
responsiveness in aged and arthritic cartilage (Verschure et al., 1996; coutts et al., 2003; 
Hickey et al., 2003). 
Evidence suggests an uncoupling of Insulin like growth factor-I responsiveness in 
osteoarthritis with Insulin like growth factor-I having the ability for robust simulation of 
matrix synthesis with an inability to decrease matrix catabolism (Morales, 2008). Despite the 
diminished ability of Insulin like growth factor-I to decrease catabolism in aged and 
osteoarthritis cartilage, studies have suggested that a combination of Insulin like growth 
factor-I and bone morphogenetic protein-7 results in greater potential for repair than either 
growth factor alone (Chubinskaya et al., 2007; Loeser et al., 2003). These studies 
demonstrated that, in general, bone morphogenetic protein-7 was more potent than Insulin 
like growth factor-I in stimulating matrix synthesis in aged and osteoarthritis cells; however, 
the greatest increase in matrix synthesis was observed after combination treatment with 
bone morphogenetic protein-7 and Insulin like growth factor-I. 
Platelet-derived growth factor is a locally produced and locally acting growth factor. It is 
synthesized by smooth muscle cells, fibroblasts, endothelial cells, and macrophages and is 
stored primarily in platelets (Lee, 2000). 
Platelet-derived growth factor plays a fundamental role in the wound healing cascade. It is 
present in high concentrations in platelets and in fluids generated during the early stage of 
wound healing (Spindler et al., 1995). Platelet-derived growth factor is a potent mitogenic 
and chemotactic factor for cells of mesenchymal origin, including fibroblasts, osteoblasts, 
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and chondrocytes, and is thus believed to be capable of enhancing tissue regeneration and 
repair. Platelet-derived growth factor receptors have been identified on a number of cell 
types, including chondrocytes, and the number of receptors is up-regulated by the presence 
of inflammatory cytokines, such as interleukin-1 (Smith et al., 1991). 
Indirect evidence for the role of Platelet-derived growth factor and other growth factors 
active in the wound healing process can be seen from the healing response in cartilage 
defects treated with microfracture. This procedure involves creation of microperforations in 
subchondral bone with an arthroscopic awl in and around a chondral lesion (Steadman et 
al., 2001). The mechanical integrity of the bone is maintained through careful placement of 
holes. The awl is driven to a depth of 2-4 mm to ensure that the marrow space is accessed 
and bleeding is observed. A clot forms in the defect, which is anchored to the bone by the 
increased surface roughness produced by the microperforations. Growth factors such as 
Platelet-derived growth factor are released into the defect site, exerting chemotactic and 
mitogenic effects on cells in the surrounding cartilage and infiltrating mesenchymal stem 
cells. This provides an enriched environment for new tissue formation, which may be 
augmented by placement of a scaffold seeded with autologous cells (Breinan et al., 2000; 
Dorotka et al., 2005). 
Platelet-derived growth factor exists as a homodimer (Platelet-derived growth factor-AA or 
Platelet-derived growth factor-BB) or a heterodimer (Platelet-derived growth factor-AB). 
Evidence to support the use of Platelet-derived growth factor in cartilage repair has been 
extrapolated from the role of Platelet-derived growth factor in wound healing or stimulation 
of matrix synthesis in growth plate chondrocytes (Schmidt et al., 2006). In vivo, when 
injected into the knee of skeletally immature rats, no adverse effects were noted in the 
cartilage or synovial membrane (Hulth et al., 1996). Presently, the most commonly used 
form of Platelet-derived growth factor is within the milieu of platelet-rich plasma, as 
discussed subsequently.  
2.2.1 Growth hormone 
Growth and homeostasis of cartilage tissue, particularly chondrocytes, during 
embryogenesis, postnatal development, and adulthood is governed by a significant number 
of humoral factors. Those factors may also be used during intrinsic or artificial repair and 
induced regeneration. Unfortunately, many of them also appear to accompany degenerative 
disease processes, such as osteoarthritis, and the question remains as to what extent they are 
involved in disease processes or whether they are actually a signature of ongoing 
endogenous repair pathways (Gaissmaier et al., 2008). 
Paracrine components can be delivered through typical nutrient supply mechanisms, ie, 
fluid flow under compressive loading, which also delivers blood based hormones, such as 
insulin and cytokines. Alternatively, certain elements are retained in the extracellular 
matrix, including Insulin-like growth factor Insulin like growth factor-1 and Insulin like 
growth factor-binding proteins, or ions, like potassium, which is the major counter ion for 
sulfate residues on glycosaminoglycans, and calcium (which is stored in mineralized 
cartilage) bound in part to matrix vesicles and chondrocalcin (collagen type II C-propeptide) 
(Gaissmaier et al., 2008). The insulin-like growth factor signaling axis is involved in 
maintenance of matrix metabolism in articular cartilage (McQuillan et al., 1986) A demise in 
metabolic control of cartilage matrix content is the hallmark of degenerative osteoarthritis 
(Mankin et al., 2000). 
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Growth hormone is an important regulator of skeletal growth and bone mineral density. It 
also stimulates cartilage growth, probably through local and systemic Insulin like growth 
factor-1 production, and possibly by direct stimulation of cartilage cell proliferation. 
Circulating Growth hormone or one of its mediators may accelerate healing of 
osteochondral defects through stimulation of osseous and chondral tissue formation (Adam 
et al., 1995).  
Until recently, the effect of exogenous Growth hormone administration in the process of 
skeletal repair has remained controversial. Bak et al. studied 36 rats with closed diaphyseal 
tibial fractures with intramedullary nailing. In this study, all rats received subcutaneous 
injections of recombinant human Growth hormone (1 mg) twice per day. Significant 
improvement in maximal stiffness and ultimate load-bearing were observed during 
evaluation performed after 40 days of healing (Bak et al., 1990). Kolbeck et al. studied 23 
dogs with experimentally-induced 3 cm ulnar bone defects and intramedullary fixation. 
Dogs were injected with recombinant bovine Growth hormone (1 mg), and several of these 
Growth hormone -treated dogs showed closure of these bone defects, while the remainder 
demonstrated healing. They reported that administration of homologous Growth hormone 
stimulates callus formation and ossification in the early phase of bone healing, which 
consequently results in increased mechanical strength and stiffness (Kolbeck et al., 2003). On 
the contrary, Growth hormone administration showed no measurable effects on fracture 
healing in a standardized tibia osteotomy rabbit model (Carpenter et al., 1992).  
Morphoangiogenesis was initially identified in the knees of adult rabbits undergoing intra-
articular Growth hormone injections for articulophyseal cartilage regeneration (Dunn, 2002). 
In this experiment, the regeneration cascade resulted in transformation of central arteries in 
subchondral osteones into tortuous, thin-walled fenestrated capillary structures containing 
erythrocytes, histiocytes, stem cells, and chondrocytes. This morphoangiogenesis might 
promote generative and constructive action in joints. The exact mechanisms of intra-
articular growth hormone are unclear; however, synovial fluid growth hormone could 
enhance proliferation, matrix synthesis, and differentiation of bone and cartilage cells in 
vitro (Goldspink & Goldberg, 1975). 
Kim et al. conducted a study of 30 rabbits with collagenase-induced osteoarthritis. After 
intra-articular collagenase injection, mature New Zealand white rabbits (n=30) were divided 
into 3 groups. Group 1 (control rabbits) received once-weekly intra-articular saline injections 
for 4 weeks. Group 2 rabbits received 6 mg hyaluronic acid injections, and group 3 rabbits 
were injected with 6 mg hyaluronic acid and 3 mg recombinant human growth hormone. 
These injections were initiated 4 weeks after collagenase injections. Lameness was observed 
for 9 weeks after collagenase injections. Macroscopic and histopathological knee joint 
findings were also evaluated at the end of 9 weeks after collagenase injections. Although all 
animals had lameness after collagenase injections, the duration and severity of lameness 
were significantly shorter and less severe in group 3 than in groups 1 and 2 (P<0.01) (Fig. 2.) 
Macroscopic scores showed that femoral condyles of group 3 rabbits received significantly 
less cartilage damage than those of rabbits in groups 1 and 2 (P<0.01) (Fig. 2.) 
Histopathological score was also the lowest in group 3 (P<0.01) (Fig. 2.)  
They reported that co-injection of intra-articular HA and recombinant human growth 
hormone may be more effective than hyaluronic acid injections alone in an osteoarthritis 
model. Novel combined therapy of hyaluronic acid with chondrocyte protective functions and 
recombinant human growth hormone with generative and constructive actions in 
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osteoarthritis-affected joints may be a promising treatment option for osteoarthritis (Kim et al., 
2011). The recombinant human growth hormone used in this study is a sustained-release 
formula, which induced continuous serum Insulin like growth factor-1 elevation for 6 days 
after a single injection. This product also exhibited greater than 95% bioavailability. Sustained 
release growth hormone was used in this study. Previously-marketed daily injections have 
provided distinct peaks and troughs of growth hormone concentrations over a period of 24 
hours. The pharmacokinetic profile of recombinant Growth hormone differs from that of 
normal physiologic growth hormone, with distinct bursts (Laursen et al., 1995). Using poly 
lactic glycolic acid microparticles for the first time, Genentech and Alkermes developed the 
Nutropin Depot® as a sustained-release human growth hormone formulation. Nutropin 
Depot® appeared to achieve stable therapeutic Insulin like growth factor-1 target levels for at 
least 14 days with higher efficacy and without supraphysiological growth hormone 
concentrations at all times. Nutropin Depot® required the fewest number of injections for 
achievement of growth hormone levels within the target range, and appealed to patients in its 
convenience and compliance. However, the poly lactic glycolic acid particle size of 
microspheres was too large for efficient suspension in an injection medium. Therefore, 
injections through a 21 to 23 gauge are inevitable. Complexities with a long-acting protein 
delivery system using poly lactic glycolic acid include inflammation and protein denaturation 
by hydrophobic interactions and harsh acidic microenvironments. These complexities decrease 
the bioavailability of Nutropin Depot® (Fu et al., 2000). However, recombinant human growth 
hormone in medium chain triglycerides can be easily injected through a 26 to 27 gauge needle 
due to the small particle size and localized lecithin on the microparticle surfaces.  
 
 
Fig. 2. (A) Gross findings of the femoral condyles in Group 1 (G1), Group 2 (2), and Group 3 
(3) rabbits. (B) histologic findings of axial sections obtained at the rectangular areas shown 
in column A photographs (H&E staining, × 40). The loss of cartilage is seen on the femoral 
condyle (black arrows). (From Kim SB, Kwon DR, Kwak H, Shin YB, Han HJ, Lee JH, Choi 
SH. Additive effects of intra-articular injection of growth hormone and hyaluronic acid in 
rabbit model of collagenase-induced osteoarthritis. J Korean Med Sci. 2010 May;25(5):776-
780; with permission.) 
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Lis evaluated diagnostic usefulness of Insulin like growth factor-1 and human growth 
hormone serum level in osteoarthritis. Twenty five patients with coxarthrosis and 16 healthy 
persons were enrolled for measurement of Insulin like growth factor-1 and human growth 
hormone concentration in serum. Insulin like growth factor-1 and human growth hormone 
serum level were assayed by enzyme-linked immunosorbent assay. No significant 
correlation was observed between human growth hormone and Insulin like growth factor-1 
in serum. Insulin like growth factor-1 concentration in patient serum was found to be 
significantly lower than that in the control group. They reported that serum concentration of 
Insulin like growth factor-1 appears to be a useful laboratory marker of osteoarthritis (Lis, 
2008). 
As previously mentioned, studies of human articular cartilage indicate that serum Insulin 
like growth factor-1 levels and chondrocyte responsiveness to Insulin like growth factor-1 
diminish progressively with age (Ashton & Matheson, 1979; Boehm et al., 2007; Fortier & 
Miller, 2006; Loeser et al., 2002; Loeser et al., 2000; Martin et al., 1997; Trippel, 1995) This 
suggests that a simultaneous decrease in the amount of Insulin like growth factor-1 available 
and a reduced ability for cells to respond to the remaining Insulin like growth factor may 
cause cartilage to be less capable of maintaining its structural and functional integrity. 
Insulin like growth factor non-responsiveness has been further observed to exist in 
chondrocytes from arthritic cartilage or in the presence of inflammation (Verschure et al., 
1996). Growth hormone stimulates cartilage growth, probably through production of local 
and systemic Insulin like growth factor-1.  
Recombinant human growth hormone is produced in laboratories. Several well known 
pharmaceutical companies manufacture recombinant human growth hormone. 
Recombinant human growth hormone is pure and free of all viruses. Recombinant human 
growth hormone has been manufactured for several years and is approved by the Food and 
Drug Administration for several uses, such as inducing growth of short children to a normal 
size. However, it has not yet been approved by the Food and Drug Administration for 
injection in joints, which is an "off-label" use. There is interest in the use of growth hormone 
as a potential osteoarthritis disease-modifying treatment; however, few studies of its effects 
in humans have been conducted. 
2.3 Platelet Rich Plasma (PRP) 
2.3.1 Basic science of PRP 
Platelets were thought to act solely in the clotting cascade. In addition to local hemostasis at 
sites of vascular injury, platelets contain an abundance of growth factors and cytokines that 
are crucial in soft tissue healing and bone mineralization (Anitua et al., 2006). Besides, we 
know that platelets also discharge many bioactive proteins responsible for attracting 
macrophages, mesenchymal stem cells, and osteoblasts, which not only promote scavenging 
of necrotic tissue but also facilitate tissue regeneration and healing (Sampson, 2008). The 
concept that application of PRP would result in improvement of cartilage repair is based on 
the physiological role of platelets in wound healing (Nurden et al., 2008). Platelet rich 
plasma is composed of 3-8 times the concentration of platelets contained in whole blood; 
therefore, it contains a hyperphysiological content of autologous growth factors. Of note, a 
universally accepted definition of platelet rich plasma in terms of concentration does not 
exist. Giusti et al., postulated that the most efficacious concentration of platelets for 
stimulation of angiogenesis in vitro was 1.5  106 platelets/L. In an adult, the normal platelet 
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count is approximately 150,000-450,000 platelets/L. (Giusti et al., 2009) There are 
classification schemes that categorize platelet concentrates based on relative concentrations 
of platelets, leucocytes, and fibrin, and, although it is important to recognize and 
understand that there are obvious differences between types of platelet concentrates that are 
being used, the general term/abbreviation, PRP, is used herein (Dohan Ehrenfest et al., 
2009). Several centrifuge devices (harvest SmartPReP APC+TM, Huons®sPRP etc) are 
commercially available for use in physicians’ offices. These devices achieve varying 
concentrations, with whole blood-to-platelet ratios ranging from 1:2 to 1:8. The ratio of 
white blood cell content also varies with the device. Obviously, the ratio of plasma to 
platelets in autologous blood is 1:1. Due to a lack of high-quality studies, the ideal ratio of 
plasma to platelets and the ideal amount of white blood cell concentrate is not well 
established at this time. 
In response to tissue injury, clots rich in platelets and fibrin form a scaffold for subsequent 
healing. There are over 1500 proteins within platelets, and, among them, are growth factors 
stored in platelets as granules, which are known to play important roles in the normal 
healing response, including Platelet-derived growth factor, vascular endothelial growth 
factor, transforming growth factor-b, fibroblast growth factor, and epidermal growth factor 
(Qureshi et al., 2009). Through modulation of the inflammatory response, promotion of local 
angiogenesis, attraction of fibroblasts and local stem cells to the site of injury, and induction 
of autocrine growth factor production by uninjured adjacent cells, platelets and their 
products are instrumental in repair and regeneration of normal tissue. 
In addition to the growth factors mentioned, there are several others that have been 
evaluated for their role in chondrogenesis, and it could be concluded that these factors will 
therefore be important during cartilage regeneration or repair. Clearly, numerous growth 
factors are needed for proper sequencing of chondrogenesis, and it is likely that more than a 
single growth factor will be needed for achievement of hyaline cartilage tissue in a 
reparative procedure. It is becoming increasingly clear that growth factors can work 
synergistically to enhance cartilage matrix synthesis, as in the case of bone morphogenetic 
protein-7 and Insulin like growth factor-I (Loeser et al., 2003), and Insulin like growth factor-
I, fibroblast growth factor-2, and transforming growth factor-b differentially regulate their 
own and each other’s gene expression and protein production in vitro (Shi et al., 2009). 
Based on the concept that a combination of bioactive growth factors is likely necessary for 
cartilage repair, and the increasing application of autogenous biologics for tissue 
engineering, recent attention has been given to the use of platelet rich plasma in cartilage 
repair techniques. Another advantage of platelet rich plasma is that on clotting; platelets 
form three-dimensional scaffolds to fill the cartilage defect and act as a guide for 
neochondrogenesis in situ. Although these issues are not insurmountable, the agents most 
likely to succeed in this regard are likely to include the polygrowth factor environment 
provided by platelet rich plasma products. 
2.3.2 History and development of PRP 
In the 1930s, Schultz demonstrated an injection technique that successfully induced 
tightening of loose temporomandibular joints; the solution injected was derived from 
psyllium seed. In the 1950s, Hackett named this technique prolotherapy to imply 
proliferation of fibrous tissue. In the early 1990s, his work was updated with articles on 
proposed mechanisms of action and use of prolotherapy (using other injectants, such as 
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dextrose and morrhuate sodium) in essentially all joints of the body. More recently, 
prolotherapy has been defined as the injection of growth factors or growth factor production 
stimulants to facilitate growth and repair of normal cells and tissue. A proliferant is any 
solution injected with the intent of growth or repair. Growth factors produced or provided 
with proliferant injection are those that are increased during the repair phase in soft tissue of 
various types; thus, connective tissue is the target for treatment. Linetsky et al proposed the 
term regenerative injection therapy to describe treatments with this goal.  
Autologous platelet rich plasma was first used in 1987 by Ferrari et al., following open heart 
surgery in order to avoid excessive transfusion of homologous blood products. Rationale: 
reversal of the blood ratio through decrease of red blood cell to 5% and increase of platelets 
to 94% for stimulation of recovery; defined as a volume of the plasma fraction of autologous 
blood having a platelet concentration above baseline; clinical efficacy with above 1 million 
platelets/ul. 
In the late 1990s, surgeons began adding platelet rich plasma to fibrin glue, forming a gel for 
placement in surgical sites. The goal was to improve healing, anchoring of implantable 
materials, and speed of recovery. In the early part of this century, physicians began injection 
of platelet rich plasma as a proliferant. The first published, nonsurgical report was a case 
series published in the podiatry field. Since 2005, the Hackett-Hemwall Foundation and the 
University of Wisconsin have sponsored an annual research forum focused on regenerative 
injection treatments. The mode of action of these therapies has been a major focus of 
discussion. Banks (Banks, 1991) has proposed that the common end point of regenerative 
therapy is formation of new collagen fibers. Growth factor stimulation by lipids released 
from cell membrane rupture and microbleeding with release of platelets have been 
proposed as potential mechanisms for such an effect (Reeves et al., 2008). Rabago et al 
discussed these proposed mechanisms of action in their review of 4 injection therapies, 
including dextrose/sodium morrhuate, polidocanol, autologous whole blood, and platelet 
rich plasma injections. They reported that the common goal of these injections is to stimulate 
a normal tissue repair cascade resulting in organized collagen fibers, not scars. Regenerative 
biomedicine is receiving progressive attention in medicine. Advancements in the study of 
these innovative bioactive therapies, such as the use of platelet rich plasma, mesenchymal 
stem cells, extracorporeal shock wave therapy, sclerosing agents, nitric oxide, and matrix 
metalloproteinase etc, have taken place during the past 2 decades.    
2.3.3 Preparation and safety of PRP 
Platelet rich plasma is prepared by centrifuging autologous, anticoagulated whole blood. 
The range of ideal concentrations is based primarily on opinion, and most publications 
differ on the platelet rich plasma concentrations cited. Citrate can be used for inhibition of 
the clotting cascade by binding ionized calcium. Centrifugation separates the following: (1) 
plasma (top layer) from (2) platelets and white blood cells (buffy coat, middle layer) and (3) 
red blood cells (bottom layer) (Fig. 3.) as a result of differences in specific gravity.  
In order to further concentrate the preparation, a second centrifugation separates the platelet 
rich plasma from platelet-poor plasma. Of note, the use of 2 spins versus 1 spin is 
controversial. Although a second spin will certainly concentrate the platelets further, the 
question of whether this step is necessary remains a subject of discussion. The platelet rich 
plasma (middle layer) is then drawn off, and addition of calcium chloride or thrombin 
activates the platelet rich plasma and results in prompt release of 70% of the growth factors 
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from the granules within 10 minutes (and nearly all of the contents within an hour). The 
issue of pre-activation is also controversial, and not all clinicians include this step. Presently, 
a number of different manufacturers have introduced systems for platelet rich plasma 
preparation, allowing for both intraoperative and outpatient use of platelet rich plasma for a 
variety of orthopaedic pathologies (Hall et al., 2009). The volume of platelet rich plasma and 
concentration of platelets yielded from a volume of whole blood can differ based on the 
preparation system used (Foster et al., 2009; Mishra et al., 2009; Hall et al., 2009). For 
example, in our clinic, we use the Huons® sPRP system (Huons®, Gyeonggido, Korea) (Fig. 
3.). The procedure utilizes a 50 ml venous blood sample, which is drawn using aseptic 
technique from the anticubital vein. Use of an 18-19 gauge butterfly needle is advised, in an 
effort to avoid irritation and trauma to platelets. Blood is then placed in a Korean Food and 
Drug Administration approved device (Huons®, Gyeonggido, Korea), centrifuged for 3 min 
at 3,200 rpm, and separated into platelet poor plasma, PRP, and RBC. Platelet poor plasma is 
extracted through a special port and discarded from the device. Afterward, the platelet rich 
plasma is withdrawn. Approximately 5.5 or 6.0 cc of platelet rich plasma is available.  
 
 
Fig. 3. Platelet rich plasma preparation. (1) Platelet poor plasma (top layer) (2) platelets and 
white blood cells (buffy coat, middle layer) and (3) red blood cells (bottom layer). PPP; 
platelet poor plasma, PRP; platelet rich  plasma, RBC; red blood cell. Photo courtesy of 
Huons® Technoloogies, sPRP kit.  
Platelet rich plasma is prepared from autologous blood; therefore, any concerns regarding 
immunogenic reactions or disease transfer are eliminated. Growth factors act on cell 
membranes, rather than on the cell nucleus, and activate normal gene expression. Growth 
factors are not mutagenic and act naturally through gene regulation and normal wound 
healing feed-back control mechanisms.  
2.3.4 Preclinical studies 
In a rabbit model, osteochondral defects were treated with either autogenous platelet rich 
plasma in a poly-lacticglycolic acid carrier, poly-lacticglycolic acid alone, or left untreated 
(Sun et al., 2010). The platelet rich plasma group demonstrated a higher extent of cartilage 
regeneration as well as increased production of glycosaminoglycans in the extracelluar 
matrix. 
Osteoarthritis models have also been used in study of the effects of platelet rich plasma on 
synovial cell biology. Cells from 10 patients were cultured and exposed to either a platelet-
poor or platelet-rich solution. Investigators found that the platelet rich solution in growth 
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factors enhanced hyaluronic acid secretion; therefore, they concluded that intra-articular 
injections of platelet-released growth factor may be useful in maintenance of joint 
homeostasis by contributing to hyaluronic acid restoration (Anitua et al., 2007).  
In the animal literature, results of several studies have demonstrated evidence of 
osteogenesis and formation of cartilaginous tissue with platelet rich plasma combined with 
chondrocytes or a collagen matrix (Qi et al., 2009). Sustained-release platelet rich plasma 
intra-articular injections also resulted in increased cartilage matrix metabolism (Saito et al., 
2009). Although chondrocytes and platelet rich plasma appeared to stimulate 
chondrogenesis subcutaneously, demineralized bone matrix and platelet rich plasma did 
not stimulate osteogenesis intramuscularly (Ranly et al., 2007) which prompts further 
questions about the substrates with which platelet rich plasma may have synergistic effects 
and the environment in which the composite is placed. Intra-articularly injected sustained-
release vehicles for platelet rich plasma appeared to stimulate cartilage matrix metabolism, 
which suggests potential uses in osteoarthritis management (Saito et al., 2009). In a canine 
model, a composite was created when platelet rich plasma was combined with bone marrow 
stromal cells and demineralized bone matrix, and then subsequently wrapped in a muscle 
flap containing blood vessels. This combination appeared to enhance osteogenesis and 
vascularization (Li et al., 2009). 
In a study of porcine mandibular bone defects, platelet rich plasma combined with bone 
marrow was found to stimulate osteogenesis (Lopez-Lopez et al., 2009). In another study, 
platelet rich plasma was combined with bone graft and stimulated osteogenesis in rabbit 
calvarium defects (Nagata et al., 2009). Chondrogenesis was demonstrated in rabbit knee 
cartilage defects when platelet rich plasma was used with a scaffold (Sun et al., 2010). 
platelet rich plasma alone also has been found to enhance the healing of diabetic fractures in 
rats (Gandhi et al., 2006).  
2.3.5 Clinical studies 
Blood-derived growth factors have already been studied for their potential to aid in cartilage 
repair and have been documented in the literature in both preclinical and clinical studies 
(Saito et al., 2009; Wu et al., 2007). In particular, Baltzer et al. (Tamoto et al., 1994) conducted 
an analysis of the effect of autologous conditioned serum in treatment of patients with knee 
osteoarthritis. In their prospective, randomized patient- and observer-blinded, placebo-
controlled trial, they demonstrated that autologous conditioned serum injections induced 
considerable improvement of the clinical signs and symptoms of osteoarthritis with results 
that are even superior to those of hyaluronic acid. Recently, there has been increasing 
interest in the use of another autologous blood product, platelet rich plasma, which might 
provide cellular and humoral mediators to promote tissue healing in a variety of 
applications. The rationale is based on the activity of blood growth factors carried in 
platelets, many of which have been shown to take part in regulation of articular cartilage 
(Kobayashi et al., 1994). Platelets contain storage pools of growth factors in their a-granules 
(Larsen et al., 1977), including Platelet-derived growth factor, Transforming Growth Factor-
b, Insulin like growth factor-1, fibroblast growth factor, and many others, as well as 
cytokines and chemokines (Sanzhez et al., 2009). Platelet rich plasma is derived from 
centrifugation of autologous whole blood and contains a platelet concentration that is 4 to 5 
times higher than that of normal blood, thus offering a high concentration of growth factors 
in physiological proportions. Some research findings have suggested a possible role for 
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platelet rich plasma in treatment of cartilage lesions (Saito et al., 2009). In an observational 
retrospective cohort study using hyaluronan injections as a control, Sanchez et al. (Sanchez 
et al., 2008) showed interesting preliminary results using intra-articular injections of an 
autologous preparation rich in growth factors  for treatment of knee osteoarthritis. These 
studies suggest that these potent biological regulators of chondrocytes have an important 
role in cartilage repair. However, for the time being, evidence for clinical use of platelet rich 
plasma is still in its infancy, particularly regarding treatment of degenerative knee 
conditions via multiple platelet rich plasma injections. A study was performed to explore 
this novel approach for treatment of articular cartilage degenerative lesions. The preliminary 
results indicated that this procedure was safe and had the potential to relieve pain and 
improve knee function and quality of life in younger patients with a low degree of articular 
cartilage degeneration. 
A number of studies investigating the use of platelet rich plasma and autologous blood have 
received attention in the popular press. However, there is still a lack of high-quality, 
prospective research providing definitive assistance to physicians in the appropriate use of 
these agents (Nguyen et al., 2011). That being said, early use of these agents for conditions 
that are often resistant to other treatments has been encouraging (Kazemi et. Al., 2010). In 
addition, platelet rich plasma and autologous blood have shown less potential for serious 
side effects, such as tendon rupture and fat necrosis, than corticosteroids. Autologous blood 
treatment protocols involve injection of a local anesthetic in the affected region and then 
performance of venipuncture and re-injection of the patient’s blood into the abnormal tissue. 
To date, no randomized controlled trials have been conducted in this area. We found an 
observational, retrospective clinical study that used hyaluronan as a control. The 
investigators used serial intra-articular platelet rich plasma injections, with modest 
outcomes. Another clinical study was prospective and showed more positive results, but did 
not include a control group. Investigators found promising results in patients of younger 
ages, patients with a lower body mass index, males, and cases of milder severity (Filardo et 
al., 2010). Application of platelet rich plasma in cartilage repair is relatively new; therefore, 
there have been limited publications investigating its use. Chondrocytes and mesenchymal 
stem cells exposed to platelet rich plasma have shown both increased cell proliferation and 
cartilage extracellular matrix synthesis of proteoglycans and collagen type II, compared with 
controls (Akeda et al., 2006). Synoviocytes from patients with osteoarthritis cultured in 
platelet rich plasma demonstrated increased hyaluronic acid production and secretion, 
suggesting that platelet rich plasma could potentially serve as an endogenous source of 
chondroprotection and joint lubrication after intra-articular application (Anitua et al., 2007). 
In a cohort of 30 patients for comparison of injections of platelet rich plasma with hyaluronic 
acid in management of osteoarthritis, the success rate for the pain subscale reached 33.4% 
for the platelet rich plasma group, compared with 10% for the hyaluronic acid group (p = 
0.004) (Sanchez et al., 2008). In addition, percent reductions in the physical function subscale 
and overall Westren Ontario and McMaster Universities (Bellamy et al., 1988) at 5 weeks 
were also associated solely with treatment modality in favor of platelet rich plasma, with p = 
0.043 and p = 0.010, respectively. Kon et al. reported results of a large, prospective case 
series using intraarticular platelet rich plasma injection in patients with degenerative 
chondral lesions of the knee, as seen on magnetic resonance image (Kellgren o, n = 58 knees) 
or clear osteoarthrosis on radiograph (Kellgren I-III, n = 33; Kellgre IV, n = 24. Injection of 5 
mL PRP (via a lateral approach without guidance) was administered every 21 days for a 
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total of 3 treatments. Calcium chloride was added for activation of platelets. A substantial 
improvement in International Knee Documentation Committee (Irrgang et al., 2001) and 
EuroQol-visual analogue scale scores (EuroQol, 2007) was noted at the end of therapy and at 
both the 6- and 12-month time points. International Knee Documentation Committee 
subjective scores as well as the EuroQol-visual analogue scale score also demonstrated 
major improvements at the end of therapy. The authors concluded that treatment with 
platelet rich plasma is safe and effective for improvement of pain, function, and quality of 
life in patients with degenerative articular pathology. No follow-up imaging was reported. 
The initial hypothesis was that the use of platelet rich plasma might stimulate chondral 
anabolism and produce a reduction in catabolic processes, thus leading to 
chondroprotective and chondroregenerative actions, and, therefore, symptomatic 
improvement. However, the clinical nature of this study makes it difficult to assess the 
disease-modifying properties of this approach. Moreover, despite the initial considerable 
improvement in clinical signs and symptoms of knee cartilage degeneration, the marked 
worsening observed at the 24-month follow-up indicates that improvement due to platelet 
rich plasma injections is mostly symptomatic, at least with this procedure. Platelet rich 
plasma probably influences overall joint homoeostasis, also through reduction of synovial 
membrane hyperplasia and modulation of the cytokine level, thus leading to the observed 
improvement in the clinical outcome, albeit only temporarily, and maybe without affecting 
cartilage tissue structure or progression of joint degeneration (Saito et al., 2009). Further 
studies will determine whether or not other application modalities, with different 
platelet/growth factor concentrations and injection times, may allow for achievement of 
better and more durable results. 
Treatment is most effective in younger male patients, with lower body mass index and 
lower degrees of chondral degeneration. The interesting results obtained regarding the 
safety, feasibility, and short-term efficacy of this treatment suggest that it may represent a 
minimally invasive and safe procedure that may be cyclically repeated in order to improve 
knee function and quality of life.  
Despite early optimism and the positive safety profile of platelet rich plasma and 
autologous blood, most insurance companies are reluctant to cover the use of these agents 
due to a lack of high-quality randomized, double-blinded studies. 
3. Conclusion 
When treating a patient with osteoarthritis, it is best to start with non-interventional 
approaches, such as physiotherapy, ice, and analgesics. If conservative treatment fails, 
injectable agents may help. Corticosteroid injections are effective in reducing pain associated 
with osteoarthritis and in treatment of conditions in which inflammation is present. When 
corticosteroid treatment is not effective for osteoarthritis, intra-articular injections with 
hyaluronic acid are another option. Hyaluronic acid injections provide longer-lasting pain 
relief than corticosteroids for patients with osteoarthritis; however, they are much more 
expensive. Growth hormone has not yet received Food and Drug Administration approval 
for injection in joints, which is an "off-label" use. There is interest in the use of growth 
hormone as a potential osteoarthritis disease-modifying treatment; however, studies of its 
effects in humans are lacking. Platelet-rich plasma and/or autologous blood injections are 
safer and may be more effective than corticosteroids for treatment of osteoarthritis. 
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However, physicians need to understand that high-quality prospective evidence as to the 
appropriate use of some of these treatments for certain conditions is lacking. Considering 
the limited data, no clear definition of a standardized platelet rich plasma treatment 
protocol has been established to date. Further research is needed.  
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